SM-030 is under clinical development by DermBiont and currently in Phase II for Melasma (Chlosma). According to GlobalData, Phase II drugs for Melasma (Chlosma) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SM-030 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SM-030 overview
SM-030 is under development for the treatment of melasma, hyperpigmentation, skin brightening and solar lentigos (sun spots). It is administered through topical route. It acts by targeting protein kinase C beta type.
DermBiont overview
DermBiont, Inc., a clinical stage precision dermatology company targeting skin diseases at their root cause. The company is headquartered in United States.
For a complete picture of SM-030’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
